Global Bacterial (Pyogenic) Meningitis Market - 2023-2030

Global Bacterial (Pyogenic) Meningitis Market - 2023-2030

Global Bacterial (Pyogenic) Meningitis Market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030, growing with a CAGR of XX% during the forecast period 2023-2030.

The global bacterial meningitis market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics such as increasing prevalence and others. Government investments are boosting the market for the development of better treatment options and will continue to drive the global market. The global bacterial meningitis industry is placing increasing emphasis to reduce its impact.

Bacterial meningitis is a serious type of meningitis and is also known as pyogenic meningitis. It causes the tissues around the brain which leads to swelling, leading to long-term complications and even death. The treatment is based on the type of the disease, including antibiotics, corticosteroids, fluid replacement therapy, oxygen therapy, and others. Antibiotics are considered a first-line treatment option for bacterial meningitis treatment.

Similarly, North America dominates the bacterial meningitis market, capturing the largest market share owing to the increasing prevalence, the region’s favorable reimbursement policies, advanced healthcare infrastructure, and the presence of major players.

Owing to the major factors such as the increasing prevalence of bacterial meningitis, increasing awareness and early detection, rising clinical trials, regulatory approvals, and research activities, increasing demand for novel therapeutics, and advancements in treatment options are expected to drive the global bacterial meningitis market over the forecast period.

Dynamics

Increasing Prevalence of Bacterial Meningitis is Expected to Drive the Growth of the Market

The increasing prevalence of bacterial meningitis is expected to drive the growth of the market over the forecast period. Bacterial meningitis is a dangerous life-threatening disease and serious infection that affects the membranes surrounding the brain and spinal cord. The increasing prevalence can further increase the demand for therapeutic innovations for better patient outcomes.

For instance, according to the National Institute of Health (NIH), the incidence of meningitis worldwide is estimated to be 20 cases per 100,000 people that is, about 1.2 million the incidence and causes vary across geographic regions. In meningitis, bacterial meningitis is the most common and more dangerous disease causing death than the other types.

Moreover, an increase in bacterial meningitis cases could raise concerns about public health. Governments, healthcare organizations, and researchers might focus on raising awareness, implementing preventive measures, and developing effective treatment options such as innovative antibiotic combinations, corticosteroid drugs, innovative vaccines and others.

Rising Clinical Trials is Also Expected to Drive the Growth of the Bacterial Meningitis Market

The continuous ongoing clinical trials are expected to drive the market share over the forecast period, by building trust in patients about the safety and efficacy of the bacterial meningitis therapeutics. The positive results from clinical trials can boost investor confidence and patient trust in the usage of medicines for bacterial meningitis treatment. This increased confidence can attract funding for further research and development and conduct more clinical trials, allowing companies to invest in more innovative therapeutics and driving the market.

For instance, on May 26, 2023, a successful trial of the NmCV-5 pentavalent vaccine suggests it could contribute to the goal of defeating epidemic meningitis. An effective, affordable vaccine against meningococcal disease has been successfully tested in Mali and The Gambia. Phase 3 clinical trial data suggests the vaccine is safe and induces a strong immune response across five strains of meningococcal bacteria: A, C, W, Y, and X.

The increasing clinical trials also increase the regulatory approvals for new treatments, such as drugs, medical devices, vaccines, or procedures, and improve the range of therapeutic options available to patients and healthcare providers. This treatment expansion choice can increase the market growth as it meets the needs of individuals who not have responded well to existing therapeutics. These increased clinical trials improve the more effective treatment options with fewer adverse effects.

For instance, on March 14, 2023, GSK plc announced positive headline results from the phase III trial (NCT04502693) evaluating the safety, tolerability, and immunogenicity of its MenABCWY combination vaccine candidate, administered as two doses given six months apart in healthy individuals aged 10-25 years. GSK’s MenABCWY vaccine candidate combines the antigenic components of its licensed meningococcal vaccines, Bexsero (MenB) and Menveo (MenACWY).

Increasing Demand for Novel Therapeutics is Also Expected to Drive the Growth of the Bacterial Meningitis Market

There is an increasing demand for novel therapeutics, which is expected to drive the global market over the forecast period. The currently available bacterial meningitis treatments and therapeutics are effective but, they show adverse effects for some patients, and there is also a need for new therapies and therapeutics that can achieve better and enhanced treatment results with lesser side effects. Novel therapeutics also aim to address the unmet needs associated with bacterial meningitis treatment by providing alternative or complementary treatment options.

For instance, on October 17, 2022, GSK plc announced that the US Food and Drug Administration (FDA) has approved a new presentation of Menveo [Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diptheria CRM197 Conjugate Vaccine] for individuals aged 10 to 55 years to help prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W. The Menveo one-vial presentation now comes in a ready-to-use single vial giving healthcare providers a more convenient option.

Moreover, the ongoing research activities on bacterial meningitis enhance treatment opportunities with better patient outcomes, and the development of innovative treatment approaches has led to the discovery of potential novel therapeutic options such as vaccines, therapies, and other combination drugs for enhanced treatment. These advancements increase the way for the introduction of novel drugs and devices with different mechanisms of action.

Adverse Effects Associated With the Treatment Will Hamper the Market's Growth

Adverse effects associated with the treatment are also expected to hamper the market growth over the forecast period. The most commonly used therapeutics for bacterial meningitis are antibiotics and corticosteroids. There are moderate to severe adverse effects associated with the using of these drugs such as nausea or vomiting, abdominal pain or cramps, diarrhea, skin rashes, vaginal yeast infections, and others.

These adverse effects may leads to seeking alternative treatment options and discontinuing the treatment due to their discomfort. This further impact the treatment effectiveness and slows the market growth. If adverse effects are discovered during the clinical trials or after the market launch, it might lead to delays in drug development and approvals.

Lack of Awareness Also Expected to Hamper the Market Growth

The lack of awareness about bacterial meningitis and its associated treatments is expected to hamper the growth of the market over the forecast period. Bacterial meningitis is a dangerous and life-threatening infection caused by different types of bacteria such as N. meningitidis, S. pneumoniae, H. influenzae, and others. The lack of awareness stops the detection and diagnosis of the disease which may leads to serious complications.

Moreover, lack of awareness also leads to delays in seeking the appropriate treatment for better treatment. Lack of awareness can also affect preventive measures such as vaccination. If individuals are unaware of the availability and importance of vaccines for bacterial meningitis, they might not take steps to protect themselves from this dangerous bacterial disease, this lack of awareness about the disease leads to death in many patients.

Segment Analysis

The global market is segmented based on disease type, treatment type, end-user and region.

The Antibiotics Segment Accounted for Approximately 37.2% of the Bacterial Meningitis Market Share

Antibiotics holds the largest market for the treatment of bacterial meningitis over the forecast period. Antibiotics are considered as first-line treatment in bacterial meningitis patients. Antibiotics such as ceftriaxone, vancomycin, ampicillin, cefepime, cefotaxime, and others are most commonly used in the treatment due to their promising results. These antibiotics have the ability to kill or inhibit the growth of the bacteria.

For instance, according to the National Institute of Health (NIH), antibiotics and supportive care are critical in all cases of bacterial meningitis. Timely administration of antibiotics is essential. Delays in the administration of 3 to 6 hours are associated with increased mortality. The identified bacteria determine antibiotic selection. Empiric treatment with ceftriaxone and vancomycin should strongly be considered if the diagnosis is going to be delayed. Patients who are immunocompromised or older than 50 should also receive ampicillin.

Moreover, antibiotics are designed to target specific types of bacteria. Bacterial meningitis can trigger an inflammatory response that can cause damage to the brain and surrounding tissues. By eliminating the bacteria, antibiotics help reduce ongoing inflammation and limit potential complications and risks associated with bacterial meningitis. Antibiotics also prevent the spread of the bacteria to the other body parts.

Geographical Penetration

North America Accounted for Approximately 39.6% of the Market Share in 2022, Owing to the Increasing Prevalence and Strong Presence of Major Players

North America region is expected to hold the largest market share over the forecast period owing to the increasing prevalence and strong presence of major players in the region. Usually, the increasing prevalence is seen in the region due to lifestyle changes, this increased prevalence increases the demand for therapeutic innovations for better treatment.

For instance, according to the National Institute of Health (NIH), in the United States, the annual incidence of bacterial meningitis is estimated approximately 1.38 cases/100,000 population with a case fatality rate of 14.3%.

Moreover, North America, especially in the United States and Canada, is well known for its strong presence of major players including pharmaceutical and medical device companies and academic and research institutes, which actively perform clinical trials and research activities. The presence of major players in the region helps in the development of effective therapeutics including vaccines and drugs.

For instance, on February 21, 2023, Vaxcyte, Inc., a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s infant Investigational New Drug application for VAX-24, its lead, 24-valent pneumococcal conjugate vaccine candidate designed to prevent invasive pneumococcal disease including pneumococcal meningitis.

Competitive Landscape
The major global players in the bacterial meningitis market include Sanofi, Merck & Co., GlaxoSmithKline plc, Pfizer Inc., Astellas Pharma, Beximco Pharmaceuticals Ltd, Fresenius Kabi AG, Matinas BioPharma, Mylan N.V., and Lupin among others.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for pharmaceutical industries worldwide, including the global bacterial meningitis market. During the pandemic, many clinical trials, research activities, and regulatory approvals for bacterial meningitis have been temporarily postponed due to the redirected focus on the COVID-19 pandemic and its related restrictions.

The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular check-ups, appointments, and consultations worldwide, this rapidly impacted bacterial meningitis patients to seek better treatment. During the pandemic, many hospitals are focused on COVID-19 cases, this reduced the focus on bacterial meningitis treatment.

Moreover, the COVID-19 pandemic severely disrupted global supply chains, impacting the transportation of raw materials such as antibiotics, meningitis vaccines, and others. Movement restrictions and border closures delayed shipments and caused drug transportation delays. Additionally, some countries faced shortages of drugs for the treatment of bacterial meningitis due to disruptions in their supply chain networks.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global bacterial meningitis market. Many clinical trials and research activities related to the bacterial meningitis are temporarily disrupted due to conflict issues in the region. The conflict has less impact mainly due to the low prevalence and absence of key market players in this region.

By Type
• Pneumococcal Meningitis
• Meningococcal Meningitis
• Listeria Monocytogenes Meningitis
• Neonatal Meningitis
• Hemophilus (Hib) Meningitis
• Others

By Treatment Type
• Antibiotics
• Corticosteroids
• Fluid Replacement Therapy
• Oxygen Therapy
• Others

By End-User
• Hospitals
• Specialty Clinics
• Academic and Research Institutes
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• On 12 July 2023, MenFive, the first conjugate vaccine to protect against the five predominant causes of meningococcal meningitis in Africa, has been prequalified by the World Health Organization (WHO). Developed through a 13-year collaboration between Serum Institute of India Pvt. Ltd. (SIIPL) and PATH, with crucial funding from the UK government’s Foreign, Commonwealth, and Development Office, MenFive protects against meningococcal serogroups A, C, W, Y, and X and is designed to eliminate annual meningitis outbreaks and epidemics in the African meningitis belt, a string of 26 countries from Senegal and The Gambia in the west to Ethiopia in the east. It is also the only vaccine that prevents meningitis caused by meningococcal group X, a pathogen increasingly implicated in meningitis outbreaks in Africa.
• On September 15, 2022, Pfizer Inc. announced positive top-line results from the pivotal Phase 3 trial (NCT04440163) assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints, with the investigational vaccine demonstrating non-inferiority to licensed vaccines for the five meningococcal serogroups that cause the majority of invasive meningococcal disease: serogroups A, B, C, W, and Y.1 Currently, MenACWY and MenB vaccines are licensed separately, and no single vaccine is available to help protect against the five serogroups.

DataM Intelligence Opinion:

According to the DataM Intelligence, bacterial meningitis, a dangerous disease that causes death and severe complications, the market is experiencing the rapid growth in recent years and is expected to grow rapidly in the coming years due to its increasing prevalence and novel therapeutic innovations for better patient outcomes. Many innovative treatment options are going to develop in the coming years by reducing the adverse effects and for effective treatment. Moreover, lack of awareness may lead to death, increased awareness and early detection may help to seek treatment. Many clinical trials and research activities are still going on for novel therapeutics like vaccines, which is expected to growth of the global market in the upcoming years.

Why Purchase the Report?
• To visualize the global bacterial meningitis market segmentation based on type, treatment type, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of bacterial meningitis market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global bacterial meningitis market report would provide approximately 61 tables, 58 figures, and 186 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies